A prospective cross-screening study on G-protein-coupled receptors: Lessons learned in virtual compound library design

Journal of Medicinal Chemistry

Volumn 55, Issue 11, 2012, Pages 5311-5325

  Sanders, Marijn P A ^a,e   Roumen, Luc ^b   Van Der Horst, Eelke ^c,f   Lane, J Robert ^c,g   Vischer, Henry F ^b   Van Offenbeek, Jody ^b,d   De Vries, Henk ^c   Verhoeven, Stefan ^d   Chow, Ken Y ^b   Verkaar, Folkert ^b,d   Beukers, Margot W ^c   McGuire, Ross ^d,h   Leurs, Rob ^b   Ijzerman, Adriaan P ^c   De Vlieg, Jacob ^a,d,e   De Esch, Iwan J P ^b   Zaman, Guido J R ^d,i   Klomp, Jan P G ^d,j   Bender, Andreas ^c,k   De Graaf, Chris ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c LEIDEN UNIVERSITY   (Netherlands)

^d MSD   (Netherlands)

^e NETHERLANDS ESCIENCE CENTER   (Netherlands)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

^g MONASH UNIVERSITY   (Australia)

^h BioAxis Research BV   (Netherlands)

ⁱ Netherlands Translational Research Center BV   (Netherlands)

^j Lead Pharma Medicine   (Netherlands)

^k UNIVERSITY OF CAMBRIDGE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A2A RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; G PROTEIN COUPLED RECEPTOR; LIGAND; SILDENAFIL; SPHINGOSINE 1 PHOSPHATE RECEPTOR;

CRYSTAL STRUCTURE; DRUG ACTIVITY; DRUG DESIGN; DRUG SCREENING; DRUG STRUCTURE; HUMAN; LIGAND BINDING; PHARMACOPHORE; PROSPECTIVE STUDY; PROTEIN INTERACTION; PROTEIN TARGETING; RECEPTOR AFFINITY; RECEPTOR BINDING; REVIEW; VALIDATION PROCESS;

ADENOSINE A2 RECEPTOR AGONISTS; ADENOSINE A2 RECEPTOR ANTAGONISTS; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADRENERGIC BETA-2 RECEPTOR ANTAGONISTS; ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; DATABASES, FACTUAL; DRUG DESIGN; DRUG PARTIAL AGONISM; HEK293 CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PURINES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RADIOLIGAND ASSAY; RECEPTORS, ADENOSINE A2; RECEPTORS, ADRENERGIC, BETA-2; RECEPTORS, LYSOSPHINGOLIPID; STOCHASTIC PROCESSES; SULFONES;

EID: 84862291381     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300280e     Document Type: Review

References (77)

1. Kubinyi, H., Muller, G., Eds. Chemogenomics in Drug Discovery: A Medicinal Chemistry Perspective; Wiley-VCH: Weinheim, Germany, 2004.
2. Bredel, M.; Jacoby, E. Chemogenomics: an emerging strategy for rapid target and drug discovery Nat. Rev. Genet. 2004, 5, 262-275
3. Harris, C. J.; Stevens, A. P. Chemogenomics: structuring the drug discovery process to gene families Drug Discovery Today 2006, 11, 880-888
4. Caron, P. R.; Mullican, M. D.; Mashal, R. D.; Wilson, K. P.; Su, M. S.; Murcko, M. A. Chemogenomic approaches to drug discovery Curr. Opin. Chem. Biol. 2001, 5, 464-470
5. Rognan, D. Chemogenomic approaches to rational drug design Br. J. Pharmacol. 2007, 152, 38-52
6. Rognan, D. Structure-based approaches to target fishing and ligand profiling Mol. Inf. 2010, 29, 176-187
7. Keiser, M. J.; Setola, V.; Irwin, J. J.; Laggner, C.; Abbas, A. I.; Hufeisen, S. J.; Jensen, N. H.; Kuijer, M. B.; Matos, R. C.; Tran, T. B.; Whaley, R.; Glennon, R. A.; Hert, J.; Thomas, K. L.; Edwards, D. D.; Shoichet, B. K.; Roth, B. L. Predicting new molecular targets for known drugs Nature 2009, 462, 175-181
8. Badrinarayan, P.; Sastry, G. N. Virtual high-throughput screening in new lead identification Comb. Chem. High Throughput Screening 2011, 14, 840-860
9. Seifert, M. H.; Kraus, J.; Kramer, B. Virtual high-throughput screening of molecular databases Curr. Opin. Drug Discovery Dev. 2007, 10, 298-307
10. Reddy, A. S.; Pati, S. P.; Kumar, P. P.; Pradeep, H. N.; Sastry, G. N. Virtual screening in drug discovery-a computational perspective Curr. Protein Pept. Sci. 2007, 8, 329-351
11. Brianso, F.; Carrascosa, M. C.; Oprea, T. I.; Mestres, J. Cross-pharmacology analysis of G protein-coupled receptors Curr. Top. Med. Chem. 2011, 11, 1956-1963
12. Mestres, J.; Gregori-Puigjane, E.; Valverde, S.; Sole, R. V. Data completeness-the Achilles heel of drug-target networks Nat. Biotechnol. 2008, 26, 983-984
13. Gaulton, A.; Bellis, L. J.; Bento, A. P.; Chambers, J.; Davies, M.; Hersey, A.; Light, Y.; McGlinchey, S.; Michalovich, D.; Al-Lazikani, B.; Overington, J. P. ChEMBL: a large-scale bioactivity database for drug discovery Nucleic Acids Res. 2012, 40, D1100-D1107
14. Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. DrugBank 3.0: a comprehensive resource for "omics" research on drugs Nucleic Acids Res. 2011, 39, D1035-D1041
15. Chen, X.; Lin, Y.; Gilson, M. K. The binding database: overview and user's guide Biopolymers 2001, 61, 127-141
16. Chen, X.; Lin, Y.; Liu, M.; Gilson, M. K. The binding database: data management and interface design Bioinformatics 2002, 18, 130-139
17. Chen, X.; Liu, M.; Gilson, M. K. BindingDB: a Web-accessible molecular recognition database Comb. Chem. High Throughput Screening 2001, 4, 719-725
18. Wang, R.; Fang, X.; Lu, Y.; Wang, S. The PDBbind database: collection of binding affinities for protein-ligand complexes with known three-dimensional structures J. Med. Chem. 2004, 47, 2977-2980
19. Wang, R.; Fang, X.; Lu, Y.; Yang, C. Y.; Wang, S. The PDBbind database: methodologies and updates J. Med. Chem. 2005, 48, 4111-4119
20. Hu, L.; Benson, M. L.; Smith, R. D.; Lerner, M. G.; Carlson, H. A. Binding MOAD (mother of all databases) Proteins 2005, 60, 333-340
21. Smith, R. D.; Hu, L.; Falkner, J. A.; Benson, M. L.; Nerothin, J. P.; Carlson, H. A. Exploring protein-ligand recognition with binding MOAD J. Mol. Graphics Modell. 2006, 24, 414-425
22. Oprea, T. I.; Allu, T. K.; Fara, D. C.; Rad, R. F.; Ostopovici, L.; Bologa, C. G. Lead-like, drug-like or "Pub-like": how different are they? J. Comput.-Aided Mol. Des. 2007, 21, 113-119
23. Okuno, Y.; Tamon, A.; Yabuuchi, H.; Niijima, S.; Minowa, Y.; Tonomura, K.; Kunimoto, R.; Feng, C. GLIDA: GPCR-ligand database for chemical genomics drug discovery-database and tools update Nucleic Acids Res. 2008, 36, D907-D912
24. Krejsa, C. M.; Horvath, D.; Rogalski, S. L.; Penzotti, J. E.; Mao, B.; Barbosa, F.; Migeon, J. C. Predicting ADME properties and side effects: the BioPrint approach Curr. Opin. Drug Discovery Dev. 2003, 6, 470-480
25. Bender, A.; Young, D. W.; Jenkins, J. L.; Serrano, M.; Mikhailov, D.; Clemons, P. A.; Davies, J. W. Chemogenomic data analysis: prediction of small-molecule targets and the advent of biological fingerprint Comb. Chem. High Throughput Screening 2007, 10, 719-731
26. van der Horst, E.; Okuno, Y.; Bender, A.; AP, I. J. Substructure mining of GPCR ligands reveals activity-class specific functional groups in an unbiased manner J. Chem. Inf. Model. 2009, 49, 348-360
27. Klabunde, T. Chemogenomic approaches to drug discovery: similar receptors bind similar ligands Br. J. Pharmacol. 2007, 152, 5-7
28. van Westen, G. J. P.; Wegner, J. K.; IJzerman, A. P.; van Vlijmen, H. W. T.; Bender, A. Proteochemometric modeling as a tool to design selective compounds and for extrapolating to novel targets Med. Chem. Commun. 2011, 2, 16-30
29. Geppert, H.; Vogt, M.; Bajorath, J. Current trends in ligand-based virtual screening: molecular representations, data mining methods, new application areas, and performance evaluation J. Chem. Inf. Model. 2010, 50, 205-216
30. Bender, A.; Jenkins, J. L.; Scheiber, J.; Sukuru, S. C.; Glick, M.; Davies, J. W. How similar are similarity searching methods? A principal component analysis of molecular descriptor space J. Chem. Inf. Model. 2009, 49, 108-119
31. Leach, A. R.; Gillet, V. J.; Lewis, R. A.; Taylor, R. Three-dimensional pharmacophore methods in drug discovery J. Med. Chem. 2010, 53, 539-558
32. Moitessier, N.; Englebienne, P.; Lee, D.; Lawandi, J.; Corbeil, C. R. Towards the development of universal, fast and highly accurate docking/scoring methods: a long way to go Br. J. Pharmacol. 2008, 153 (Suppl. 1) S7-S26
33. Sanders, M. P. A.; McGuire, R.; Roumen, L.; De Esch, I. J.; de Vlieg, J.; Klomp, J. P. G.; de Graaf, C. From the protein's perspective: the benefits and challenges of protein structure-based pharmacophore modeling MedChemComm 2011, 3, 28-38
34. de Graaf, C.; Rognan, D. Customizing G Protein-coupled receptor models for structure-based virtual screening Curr. Pharm. Des. 2009, 15, 4026-4048
35. Liu, X.; Ouyang, S.; Yu, B.; Liu, Y.; Huang, K.; Gong, J.; Zheng, S.; Li, Z.; Li, H.; Jiang, H. PharmMapper server: a Web server for potential drug target identification using pharmacophore mapping approach Nucleic Acids Res. 2010, 38, W609-W614
36. Rask-Andersen, M.; Almen, M. S.; Schioth, H. B. Trends in the exploitation of novel drug targets Nat. Rev. Drug Discovery 2011, 10, 579-590
37. Szabo, N.; Kincses, Z. T.; Vecsei, L. Novel therapy in Parkinson's disease: adenosine A(2A) receptor antagonists Expert Opin. Drug Metab. Toxicol. 2011, 7, 441-455
38. Dorsam, R. T.; Gutkind, J. S. G-Protein-coupled receptors and cancer Nat. Rev. Cancer 2007, 7, 79-94
39. Cherezov, V.; Rosenbaum, D. M.; Hanson, M. A.; Rasmussen, S. G.; Thian, F. S.; Kobilka, T. S.; Choi, H. J.; Kuhn, P.; Weis, W. I.; Kobilka, B. K.; Stevens, R. C. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor Science 2007, 318, 1258-1265
40. Jaakola, V. P.; Griffith, M. T.; Hanson, M. A.; Cherezov, V.; Chien, E. Y.; Lane, J. R.; Ijzerman, A. P.; Stevens, R. C. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist Science 2008, 322, 1211-1217
41. Hanson, M. A; Roth, C. B.; Jo, E.; Griffith, M. T.; Scott, F. L.; Reinhart, G.; Desale, H.; Clemons, B.; Cahalan, S. M.; Schuerer, S. C.; Sanna, M. G.; Han, G. W.; Kuhn, P.; Rosen, H.; Stevens, R. C. Crystal structure of a lipid G protein-coupled receptor. Science 2012, 335, 851-855
42. Xu, F.; Wu, H.; Katritch, V.; Han, G. W.; Jacobson, K. A.; Gao, Z. G.; Cherezov, V.; Stevens, R. C. Structure of an agonist-bound human A2A adenosine receptor Science 2011, 332, 322-327
43. Jiang, Q.; Van Rhee, A. M.; Kim, J.; Yehle, S.; Wess, J.; Jacobson, K. A. Hydrophilic side chains in the third and seventh transmembrane helical domains of human A2A adenosine receptors are required for ligand recognition Mol. Pharmacol. 1996, 50, 512-521
44. Kim, J.; Wess, J.; van Rhee, A. M.; Schoneberg, T.; Jacobson, K. A. Site-directed mutagenesis identifies residues involved in ligand recognition in the human A2a adenosine receptor J. Biol. Chem. 1995, 270, 13987-13997
45. Kim, J.; Jiang, Q.; Glashofer, M.; Yehle, S.; Wess, J.; Jacobson, K. A. Glutamate residues in the second extracellular loop of the human A2a adenosine receptor are required for ligand recognition Mol. Pharmacol. 1996, 49, 683-691
46. Moro, S.; Gao, Z. G.; Jacobson, K. A.; Spalluto, G. Progress in the pursuit of therapeutic adenosine receptor antagonists Med. Res. Rev. 2006, 26, 131-159
47. Strader, C. D.; Sigal, I. S.; Candelore, M. R.; Rands, E.; Hill, W. S.; Dixon, R. A. Conserved aspartic acid residues 79 and 113 of the beta-adrenergic receptor have different roles in receptor function J. Biol. Chem. 1988, 263, 10267-10271
48. Strader, C. D.; Sigal, I. S.; Register, R. B.; Candelore, M. R.; Rands, E.; Dixon, R. A. Identification of residues required for ligand binding to the beta-adrenergic receptor Proc. Natl. Acad. Sci. U.S.A. 1987, 84, 4384-4388
49. Liapakis, G.; Ballesteros, J. A.; Papachristou, S.; Chan, W. C.; Chen, X.; Javitch, J. A. The forgotten serine. A critical role for Ser-2035.42 in ligand binding to and activation of the beta 2-adrenergic receptor J. Biol. Chem. 2000, 275, 37779-37788
50. Suryanarayana, S.; Kobilka, B. K. Amino acid substitutions at position 312 in the seventh hydrophobic segment of the beta 2-adrenergic receptor modify ligand-binding specificity Mol. Pharmacol. 1993, 44, 111-114
51. Strader, C. D.; Candelore, M. R.; Hill, W. S.; Sigal, I. S.; Dixon, R. A. Identification of two serine residues involved in agonist activation of the beta-adrenergic receptor J. Biol. Chem. 1989, 264, 13572-13578
52. Wieland, K.; Zuurmond, H. M.; Krasel, C.; Ijzerman, A. P.; Lohse, M. J. Involvement of Asn-293 in stereospecific agonist recognition and in activation of the beta 2-adrenergic receptor Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 9276-9281
53. Kikkawa, H.; Isogaya, M.; Nagao, T.; Kurose, H. The role of the seventh transmembrane region in high affinity binding of a beta 2-selective agonist TA-2005 Mol. Pharmacol. 1998, 53, 128-134
54. Pham, T. C.; Fells, J. I., Sr.; Osborne, D. A.; North, E. J.; Naor, M. M.; Parrill, A. L. Molecular recognition in the sphingosine 1-phosphate receptor family J. Mol. Graphics Modell. 2008, 26, 1189-1201
55. Parrill, A. L.; Wang, D.; Bautista, D. L.; Van Brocklyn, J. R.; Lorincz, Z.; Fischer, D. J.; Baker, D. L.; Liliom, K.; Spiegel, S.; Tigyi, G. Identification of Edg1 receptor residues that recognize sphingosine 1-phosphate J. Biol. Chem. 2000, 275, 39379-39384
56. Wang, D. A.; Lorincz, Z.; Bautista, D. L.; Liliom, K.; Tigyi, G.; Parrill, A. L. A single amino acid determines lysophospholipid specificity of the S1P1 (EDG1) and LPA1 (EDG2) phospholipid growth factor receptors J. Biol. Chem. 2001, 276, 49213-49220
57. Surgand, J. S.; Rodrigo, J.; Kellenberger, E.; Rognan, D. A chemogenomic analysis of the transmembrane binding cavity of human G-protein-coupled receptors Proteins 2006, 62, 509-538
58. van Loenen, P. B.; de Graaf, C.; Verzijl, D.; Leurs, R.; Rognan, D.; Peters, S. L.; Alewijnse, A. E. Agonist-dependent effects of mutations in the sphingosine-1-phosphate type 1 receptor Eur. J. Pharmacol. 2011, 667, 105-112
59. van der Horst, E.; van der Pijl, R.; Mulder-Krieger, T.; Bender, A.; IJzerman, A. P. Substructure-based virtual screening for adenosine A2A receptor ligands ChemMedChem 2011, 6, 2302-2311
60. Sanders, M. P.; Verhoeven, S.; De Graaf, C.; Roumen, L.; Vroling, B.; Nabuurs, S. B.; de Vlieg, J.; Klomp, J. P. Snooker: a structure-based pharmacophore generation tool applied to class A GPCRs J. Chem. Inf. Model. 2011, 51, 2277-2292
61. Wawer, M.; Bajorath, J. Similarity-potency trees: a method to search for SAR information in compound data sets and derive SAR rules J. Chem. Inf. Model. 2010, 50, 1395-409
62. Steffen, A.; Kogej, T.; Tyrchan, C.; Engkvist, O. Comparison of molecular fingerprint methods on the basis of biological profile data J. Chem. Inf. Model. 2009, 49, 338-347
63. Lee, H. G.; Kim, W. M.; Choi, J. I.; Yoon, M. H. Roles of adenosine receptor subtypes on the antinociceptive effect of sildenafil in rat spinal cord Neurosci. Lett. 2010, 480, 182-185
64. Salloum, F. N.; Das, A.; Thomas, C. S.; Yin, C.; Kukreja, R. C. Adenosine A(1) receptor mediates delayed cardioprotective effect of sildenafil in mouse J. Mol. Cell. Cardiol. 2007, 43, 545-551
65. Wang, H.; Liu, Y.; Huai, Q.; Cai, J.; Zoraghi, R.; Francis, S. H.; Corbin, J. D.; Robinson, H.; Xin, Z.; Lin, G.; Ke, H. Multiple conformations of phosphodiesterase-5: implications for enzyme function and drug development J. Biol. Chem. 2006, 281, 21469-21479
66. Gozalbes, R.; Rolland, C.; Nicolai, E.; Paugam, M.; Coussy, L.; Horvath, D.; Barbosa, F.; Mao, B.; Revah, F.; Froloff, N. QSAR strategy and experimental validation for the development of a GPCR focused library QSAR Comb. Sci. 2005, 24, 508-516
67. Goldstein, D. M.; Gray, N. S.; Zarrinkar, P. P. High-throughput kinase profiling as a platform for drug discovery Nat. Rev. Drug Discov. 2008, 7, 391-397
68. Sanders, M. P.; Fleuren, W. W.; Verhoeven, S.; van den Beld, S.; Alkema, W.; de Vlieg, J.; Klomp, J. P. ss-TEA: entropy based identification of receptor specific ligand binding residues from a multiple sequence alignment of class A GPCRs BMC Bioinf. 2011, 12, 332
69. Gasteiger, J.; Rudolph, C.; Sadowski, J. Automatic generation of 3D-atomic coordinates for organic molecules Tetrahedron Comput. Methodol. 1990, 3, 537-547
70. Liu, X.; Bai, F.; Ouyang, S.; Wang, X.; Li, H.; Jiang, H. Cyndi: a multi-objective evolution algorithm based method for bioactive molecular conformational generation BMC Bioinf. 2009, 10, 101
71. Irwin, J. J.; Shoichet, B. K. ZINC-a free database of commercially available compounds for virtual screening J. Chem. Inf. Model. 2005, 45, 177-182
72. Nijssen, S.; Kok, J. N. A Quickstart in Frequent Structure Mining Can Make a Difference. Proceedings of the 10th ACM SIGKDD International Conference on Knowledge Discovery and Data Mining, 2004; Kohavi, R.; Gehrke, J.; DuMouchel, W.; Ghosh, J., Eds.; ACM: New York, 2004; pp 647-652.
73. Del Rio, A.; Barbosa, A. J.; Caporuscio, F.; Mangiatordi, G. F. CoCoCo: a free suite of multiconformational chemical databases for high-throughput virtual screening purposes Mol. BioSyst. 2010, 6, 2122-2128
74. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 2001, 46, 3-26
75. Wenlock, M. C.; Austin, R. P.; Barton, P.; Davis, A. M.; Leeson, P. D. A comparison of physiochemical property profiles of development and marketed oral drugs J. Med. Chem. 2003, 46, 1250-1256
76. Verzijl, D.; Storelli, S.; Scholten, D. J.; Bosch, L.; Reinhart, T. A.; Streblow, D. N.; Tensen, C. P.; Fitzsimons, C. P.; Zaman, G. J.; Pease, J. E.; de Esch, I. J.; Smit, M. J.; Leurs, R. Noncompetitive antagonism and inverse agonism as mechanism of action of nonpeptidergic antagonists at primate and rodent CXCR3 chemokine receptors J. Pharmacol. Exp. Ther. 2008, 325, 544-555
77. van der Lee, M. M. C.; Bras, M.; van Koppen, C. J.; Zaman, G. J. R. beta-Arrestin recruitment assay for the identification of agonists of the sphingosine 1-phosphate receptor EDG1 J. Biomol. Screening 2008, 13, 986-998